Targeting Drugs with a Special Polysarcosine Polymer Chain
This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight.
Patent Number
US 20250057964
Status
Active
Filing Date
September 24, 2024
Grant Date
—
Expiration
September 24, 2044
Claims
21
Assignee
Mablink Bioscience SAS
Inventors
Warren VIRICEL
Citations
0 forward · 0 backward
What it covers
This patent describes a Ligand-Drug-Conjugate (LDC) compound designed to deliver a drug, typically a cytotoxic drug, to a specific target in the body. The LDC (formula XV) uses a 'single molecular weight homopolymer' (Claim 1), which is preferably polysarcosine (Claim 2). This special polymer is connected to the drug via an 'orthogonal connector' (L), ensuring the polymer is positioned distinctly from the drug and its linker (X-D). The drug (D) can be released from the LDC using an optional 'cleavable moiety' (X), which might be triggered by conditions in the body, like acidic environments in lysosomes (Claim 9). For example, a cancer-targeting antibody (the ligand, Claim 5) could be attached to this polysarcosine chain, which then carries a chemotherapy drug directly to tumor cells, releasing it only when it reaches the target.
What it doesn't cover
- —Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (Claim 1).
- —Does not cover LDCs where the polymer is not a 'homopolymer' (Claim 1), meaning it would not cover conjugates made with copolymers or other polymer types.
- —Does not cover LDCs that use polymers other than polysarcosine as the single molecular weight homopolymer (Claim 2).
- —Does not cover LDCs where the polymer is not in an 'orthogonal orientation' with respect to the drug and its linker (Claim 1).
- —Does not cover drug conjugates where the drug is not attached via an 'orthogonal connector' (L) as defined (Claim 1).
The clever bit
The clever bit is using a 'single molecular weight homopolymer,' specifically polysarcosine, as the polymer component in a drug conjugate. This provides precise control over the polymer's size and properties, which can improve drug stability and reduce variability in how the drug behaves in the body.
Why it matters
Ligand-Drug-Conjugates are a crucial class of medicines, especially for treating cancer, because they can deliver potent drugs directly to diseased cells while sparing healthy ones. Using a 'single molecular weight' polysarcosine polymer, as claimed, could lead to more consistent drug products with predictable behavior in the body. This precision might reduce side effects and improve treatment effectiveness compared to conjugates made with polymers that have varying chain lengths. This approach aims to enhance the stability and targeting capabilities of these complex therapeutic molecules.
Real-world examples
- 1.Antibody-drug conjugates (ADCs) in cancer therapy
- 2.Targeted drug delivery systems for chemotherapy
- 3.Biologics with enhanced half-life or reduced immunogenicity
- 4.Polysarcosine-based drug carriers
Generated by PatentBrief · Not legal advice · patentbrief.org
US 20250057964 · 2026